<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1109084</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2023.1109084</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Pharmacokinetic study of <italic>Strongylocentrotus nudus</italic> egg polysaccharide in rats and beagles using a <sup>3</sup>H-labeling method</article-title>
<alt-title alt-title-type="left-running-head">Xing et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2023.1109084">10.3389/fphar.2023.1109084</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Xing</surname>
<given-names>Han</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Xiaojie</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liao</surname>
<given-names>Jianmin</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kong</surname>
<given-names>Ying</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lu</surname>
<given-names>Yayuan</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Di</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Ning</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/373939/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chen</surname>
<given-names>Xijing</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/807691/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Qin</surname>
<given-names>Zhiying</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2055234/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Pharmacy</institution>, <institution>First Affiliated Hospital of Zhengzhou University</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Henan Key Laboratory of Precision Clinical Pharmacy</institution>, <institution>Zhengzhou University</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Henan Engineering Research Center for Application and Translation of Precision Clinical Pharmacy</institution>, <institution>Zhengzhou University</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Clinical Pharmacokinetics Laboratory</institution>, <institution>China Pharmaceutical University</institution>, <addr-line>Nanjing</addr-line>, <addr-line>Jiangsu Province</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/460026/overview">Xin Wang</ext-link>, East China Normal University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1554750/overview">Guo Ma</ext-link>, Fudan University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2163713/overview">Feng Shao</ext-link>, Nanjing Medical University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Zhiying Qin, <email>zdyqinzhiying@163.com</email>; Xijing Chen, <email>chenxj-lab@hotmail.com</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Drug Metabolism and Transport, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>03</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1109084</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>11</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>02</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Xing, Zhu, Liao, Kong, Lu, Zhao, Li, Chen and Qin.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Xing, Zhu, Liao, Kong, Lu, Zhao, Li, Chen and Qin</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>
<italic>Strongylocentrotus nudus</italic> egg polysaccharide (SEP) extracted from sea urchins has potential anticancer activity. However, little is known about its pharmacokinetic properties. To investigate the pharmacokinetics of SEP, it was radiolabeled with tritium. Furthermore, a sensitive, selective, and rapid liquid scintillation counter (LSC) method for quantifying <sup>3</sup>H-SEP in biological matrix was validated. The lower quantification limit of the method was 4 Bq. The relative standard deviations (RSDs) of the intra- and inter-day precision were &#x3c;3.0% and &#x3c;3.9%, respectively. <sup>3</sup>H-SEP was successfully applied to investigate the pharmacokinetics of SEP after intravenous administration of 20, 40, and 80&#xa0;mg/kg (40&#xa0;&#x3bc;Ci/kg) in rats and 5, 10, and 20&#xa0;mg/kg (6&#xa0;&#x3bc;Ci/kg) in beagles. The AUC<sub>(0-t)</sub> of SEP at three different doses was 487.81 &#xb1; 39.99&#xa0;mg/L&#x2a;h, 1,003.10 &#xb1; 95.94&#xa0;mg/L&#x2a;h, and 2,188.84 &#xb1; 137.73&#xa0;mg/L&#x2a;h in rats and 144.12 &#xb1; 3.78&#xa0;mg/L&#x2a;h, 322.62 &#xb1; 28.03&#xa0;mg/L&#x2a;h, and 754.17 &#xb1; 37.79&#xa0;mg/L&#x2a;h in beagles. The terminal elimination half-life (t<sub>1/2</sub>) of SEP was longer in beagles (204.29 &#xb1; 139.34&#xa0;h) than in rats (35.48 &#xb1; 6.04&#xa0;h). The concentration of SEP in plasma declined rapidly in both rats and beagles. All the study results provide detailed pharmacokinetic profiles of SEP in two kinds of animals, which will be helpful for further development.</p>
</abstract>
<kwd-group>
<kwd>
<italic>Strongylocentrotus nudus</italic> egg polysaccharide</kwd>
<kwd>
<sup>3</sup>H-labeling method</kwd>
<kwd>pharmacokinetics</kwd>
<kwd>tritium</kwd>
<kwd>beagles</kwd>
<kwd>rats</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Cancer treatment is still a problem around the world. We are continuously seeking an antineoplastic therapy with minor side effects. Compared with other treatments like surgery and radiotherapy, the use of cancer drugs&#x2014;including chemotherapy and biologics&#x2014;is currently the most effective treatment for metastatic cancers (<xref ref-type="bibr" rid="B1">Behranvand et al., 2022</xref>). The development of anticancer compounds brings new hope to cancer treatment. Unfortunately, even patients treated with advanced therapies and techniques can survive for only a few months due to the severe toxicity and side effects caused by anticancer compounds (<xref ref-type="bibr" rid="B26">Zraik and He&#xdf;-Busch, 2021</xref>). For example, doxorubicin and paclitaxel exert eminent effects on liver, breast, ovarian, and lung cancer. However, their application is limited due to their acute and chronic adverse effects. The most representative side effect is the dose-limiting myelosuppression and cardiac toxicity caused by doxorubicin; nausea and vomiting are also very common (<xref ref-type="bibr" rid="B11">Li et al., 2018</xref>; <xref ref-type="bibr" rid="B24">Zhu and Lin, 2021</xref>). Thus, side effects have also been considered in screening new anticancer compounds. Compared with chemotherapy drugs, biological macromolecules, especially natural active compounds including polysaccharides, may have a bright future in the treatment of human malignancies with fewer side effects. Natural drug therapy seems to be a safe and effective option for cancer patients because its main anticancer mechanism is to enhance the immune response of the host organism.</p>
<p>Polysaccharides are natural biological macromolecules derived from fungi, marine organisms, plants, lichens, and animals (<xref ref-type="bibr" rid="B14">Ooi and Liu, 2000</xref>). Previous studies have shown that polysaccharides and polysaccharide&#x2013;protein complexes exhibit significant anticancer activities and increase the efficacy of other small-molecule chemotherapy drugs (<xref ref-type="bibr" rid="B25">Zong et al., 2012</xref>; <xref ref-type="bibr" rid="B23">Zhang et al., 2017</xref>; <xref ref-type="bibr" rid="B18">Wang M. et al., 2011</xref>; <xref ref-type="bibr" rid="B19">Xie et al., 2019</xref>; <xref ref-type="bibr" rid="B16">Wang et al., 2020</xref>). Polysaccharides are superior in inhibiting tumor metastasis. The main characteristic of polysaccharides with immune activity is the importance of their structure&#x2013;function relationships (<xref ref-type="bibr" rid="B2">Chang, 2002</xref>). <italic>Strongylocentrotus nudus</italic> egg polysaccharide (SEP), a <italic>D</italic>-glucan containing an <italic>&#x3b1;</italic>-1, 4-linked backbone and <italic>&#x3b1;</italic>-1, 3-linked branches (structure shown in <xref ref-type="fig" rid="F1">Figure 1</xref>), is extracted and purified from <italic>Strongylocentrotus nudus</italic> (sea urchins) eggs. This polysaccharide is widely accepted as a bioactive anticancer compound with profound inhibitory effects on tumor growth (<xref ref-type="bibr" rid="B7">Gao et al., 2011</xref>), which are closely related to its immunomodulatory biological activity. Numerous pharmacological studies have indicated that SEP is an anticancer candidate working through the following mechanisms: 1) promoting anti-lung cancer ability by mediating NK cytotoxicity via TLR2 and TLR4 (<xref ref-type="bibr" rid="B9">Ke et al., 2014</xref>); 2) preventing hepatocarcinoma by enhancing host immune system function, including by stimulating splenocyte proliferation and IL-2 and TNF secretion, as well as elevating immune globulin levels in the serum (<xref ref-type="bibr" rid="B18">Wang M. et al., 2011</xref>); 3) upregulating IL-2, TNF-&#x3b1;, and IFN-&#x3b3; mRNA expression (<xref ref-type="bibr" rid="B13">Liu et al., 2008a</xref>); and 4) increasing mRNA expression of inducible nitric oxide synthase (iNOS) (<xref ref-type="bibr" rid="B12">Liu et al., 2008b</xref>). Furthermore, it has been proven that SEP can work against myelosuppression and immunosuppression in cyclophosphamide-treated mice (<xref ref-type="bibr" rid="B17">Wang H. et al., 2011</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Chemical structure of SEP.</p>
</caption>
<graphic xlink:href="fphar-14-1109084-g001.tif"/>
</fig>
<p>As SEP is a biological macromolecule with a molecular weight of 6.78&#x2a;10<sup>5</sup>&#xa0;Da, it is difficult to determine its concentration in the biological matrix by traditional methods, such as LC-MS/MS and HPLC-UV. In a previous report, SEP was analyzed through the fluorescence labeling method (<xref ref-type="bibr" rid="B3">Dalvie, 2000</xref>). However, this method failed to distinguish the behavior of SEP and FITC-SEP in rats by ignoring the impact of FITC on SEP. The pharmacokinetic study of macromolecules has always been a challenge. To solve this problem, many efforts have been made in past reports, and the isotope-labeling tracer method has been proven to be a more appropriate way to study the pharmacokinetics of bio-macromolecular drugs in animals. For example, the tritium labeling method was employed by <xref ref-type="bibr" rid="B8">Jiang et al. (2015</xref>) to study the D-peptide D3 in mice; the <sup>3</sup>H-labeling method was used to obtain the pharmacokinetic behaviors of calf thymus DNA in rats and beagles (<xref ref-type="bibr" rid="B21">Yang et al., 2012a</xref>; <xref ref-type="bibr" rid="B20">Yang et al., 2014</xref>). Compared with former methods, such as LC-MS/MS and HPLC-UV, the isotope-labeling method has the advantages of being sensitive, accurate, and conforming to physiological conditions <italic>in vivo</italic> (<xref ref-type="bibr" rid="B5">Edelmann, 2022</xref>). Thus, in the present study, SEP was radiolabeled and quantified using a sensitive liquid scintillation counter (LSC) method, and its pharmacokinetic profile in rats and beagles was investigated.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>2 Materials and methods</title>
<sec id="s2-1">
<title>2.1 Chemicals and reagents</title>
<p>Unlabeled SEP was provided by the School of Life Science and Technology, China Pharmaceutical University (Nanjing, China). Scintillation fluid was from PerkinElmer Life Science (Boston, MA). Isopropanol was purchased from Tedia (USA). Purified water was prepared using the Milli-Q water purification system (Millipore, USA). Other chemicals used in the experiment were commercially available analytical reagents.</p>
</sec>
<sec id="s2-2">
<title>2.2 Radiolabeling of SEP</title>
<p>Radiolabeled SEP was synthesized using an isotope exchange method. Specifically, a certain amount of SEP was dissolved in deionized water, and then 10% palladium/carbon (Pd/C) was added as catalyst. A round-bottomed flask with a magnetic stir bar was attached to a gas transfer manifold. The contents were frozen with liquid nitrogen, and tritium gas was added via standard vacuum transfer techniques. Then, the exchange reaction was conducted at 25&#xb0;C with continuous stirring for 40&#xa0;h. The tritium gas was finally removed, and the reaction was terminated with freezing liquid nitrogen.</p>
</sec>
<sec id="s2-3">
<title>2.3 Radiochemical purity detection</title>
<p>Thin-layer chromatography (TLC) was applied to analyze the radiochemical purity of <sup>3</sup>H-SEP. <sup>3</sup>H-SEP was dissolved in water. The sample was dotted at one corner of the thin-layer silica gel plate and developed at room temperature with methanol. After the sample had dried, the plate was pressed, exposed, and scanned on a phosphor screen imager.</p>
</sec>
<sec id="s2-4">
<title>2.4 Sample preparation</title>
<p>An aliquot of 50&#xa0;&#x3bc;L rat plasma sample was transferred into a liquid flash bottle. A volume of 1&#xa0;mL of scintillation cocktail was added and mixed for 1&#xa0;min before analysis.</p>
</sec>
<sec id="s2-5">
<title>2.5 Method validation</title>
<sec id="s2-5-1">
<title>2.5.1 Background value and calibration curve</title>
<p>The detection of background value was carried out to obtain credible data by analyzing eight batches of blank plasma.</p>
<p>Calibration curve samples consisted of radioactive/non-radioactive SEP-mixed solution at seven radioactivity levels and blank plasma. The detection of <sup>3</sup>H-SEP was treated as ordinates (Y) and the theoretical ones as abscissa (X). The range of the calibration curves for both rats and beagles was 4&#x2013;400 Bq. The linearity of the method was evaluated by a least-squares linear regression to obtain calibration equations containing eight non-zero concentrations.</p>
<p>Limit of detection (LOD) was calculated based on background value.</p>
</sec>
<sec id="s2-5-2">
<title>2.5.2 Accuracy and precision</title>
<p>Accuracy and precision were determined using five replicate runs at three levels of quality control (QC) and LLOQ samples on three consecutive days. Relative error (RE) and relative standard deviation (RSD) were adopted to express accuracy and precision, respectively. Percentage of accuracy within &#xb1;15%, and inter-and intra-day precision not beyond 15% were accepted for QC samples, except for the LLOQ, which should be within 20%.</p>
</sec>
<sec id="s2-5-3">
<title>2.5.3 Quenching effect</title>
<p>The quenching effect in the <sup>3</sup>H-labeled experiment was equal to the recovery or matrix effect in traditional pharmacokinetic studies. Five replicate samples, of three different levels mixed with blank plasma, were compared with three levels of working solutions. The ratio of the radioactivity of samples with blank plasma to the radioactivity of working solutions was investigated to estimate the quenching effect.</p>
</sec>
<sec id="s2-5-4">
<title>2.5.4 Stability</title>
<p>The stability of <sup>3</sup>H-SEP in plasma was estimated by analyzing five replicates in four situations: at room temperature (25&#xb0;C) for 4 h, at 4&#xb0;C for 24&#xa0;h, at &#x2212;20&#xb0;C for 30 days, and in three freeze&#x2013;thaw cycles from &#x2212;20&#xb0;C to room temperature.</p>
</sec>
</sec>
<sec id="s2-6">
<title>2.6 Pharmacokinetic studies</title>
<p>Sprague&#x2013;Dawley rats (220 &#xb1; 10&#xa0;g) and beagles (11.0 &#xb1; 0.5&#xa0;kg) were purchased from Shanghai Sippr-BK Laboratory Animal Co. Ltd (Shanghai, China) and Nanjing Yadong Biotechnology Co. Ltd (Nanjing, China), respectively. The rats and dogs were kept in an environment with a 12-h-on/12-h-off cycle and constant temperature and humidity. All animals were fasted for 12&#xa0;h before the experiment, with free access to water. All animal studies were carried out according to standard operating procedures, and the ethical norms were approved by the Animal Ethics Committee of China Pharmaceutical University.</p>
<p>To achieve the desired SEP concentration, non-labeled SEP was added to radioactive working solution. The radioactivity of the animal experiment was 40&#xa0;&#x3bc;Ci/kg for rats and 6&#xa0;&#x3bc;Ci/kg for beagles. A total of 18 SD rats of each gender were divided randomly into three groups of six rats. Low (20&#xa0;mg/kg, the ratio between cold and hot SEP: 319:1), middle (40&#xa0;mg/kg, the ratio between cold and hot SEP: 639:1), and high (80&#xa0;mg/kg, the ratio between cold and hot SEP: 1,279:1) levels of SEP and <sup>3</sup>H-SEP solutions of physiological saline were administered by intravenous tail injection once per day for single-dose administration and multiple doses each day consecutively for 7&#xa0;days for multiple-dose administration. Blood samples of rats were collected in heparinized tubes via the orbital venous plexus before dosing and at 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96&#xa0;h after administration.</p>
<p>The beagle study also consisted of three groups, with four dogs in each group. The doses of SEP in beagle dogs were 5&#xa0;mg/kg, 10&#xa0;mg/kg, and 20&#xa0;mg/kg, and the ratios of cold to hot SEP were 79:1, 159:1, and 319:1, respectively. The administration dosage was determined according to previous pharmacodynamic studies, and the experimental operation is described in the previous paragraph. Biological samples from dogs were obtained from a forelimb vein, and the sampling times were 0, 0.033, 0.083, 0.25, 0.5, 1, 2, 6, 12, 24, 48, 72, and 96&#xa0;h after dosing. All samples were centrifuged immediately at 8,000&#xa0;rpm for 5&#xa0;min to obtain the plasma and were stored at &#x2212;20&#xb0;C to avoid transformation between <sup>3</sup>H-labeled SEP and H<sub>2</sub>O.</p>
</sec>
<sec id="s2-7">
<title>2.7 Data analysis</title>
<p>Pharmacokinetic parameters were calculated by a non-compartmental model using Drug and Statistics (version 2.1, Mathematical Pharmacology Professional Committee of China, Shanghai, China). Data were expressed as mean values &#xb1; standard deviation (mean &#xb1; SD).</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>3 Results</title>
<sec id="s3-1">
<title>3.1 Radioactivity verification of <sup>3</sup>H-labeled SEP</title>
<p>In the present study, isotope exchange was applied to synthesize <sup>3</sup>H-labeled SEP. According to the data of phosphorimager scans, the radioactivity of <sup>3</sup>H-labeled SEP determined by TLC was more than 97%, which is sufficient to study the pharmacokinetics of <sup>3</sup>H-SEP in rats and beagles. Analysis of diluted <sup>3</sup>H-SEP from the initial radioactive products produced three measurements that demonstrated the total radioactivity of <sup>3</sup>H-SEP to be 2.8&#xa0;mCi. The specific activity of final preparation, as measured using the refractive index detector and liquid scintillation counter, was 0.64&#xa0;mCi/mg.</p>
</sec>
<sec id="s3-2">
<title>3.2 Method validation</title>
<p>As a kind of biological macromolecule, polysaccharides require special consideration in the choice of research methods. Compared with other analytical methods, the isotope tracer method was selected for its high sensitivity and because it causes no changes in the properties of the drug itself. The whole process of sample determination is convenient, simple, and fast. The LSC method used to determine <sup>3</sup>H-SEP in plasma was fully validated for calibration, accuracy, precision, stability, and LLOQ according to the US FDA guidelines (U.S. Food and Drug Administration Bioanalytical Method Validation Guidance for Industry [2018]), followed by further instructions, including background, quenching effect, and tritium&#x2013;water exchange rate.</p>
<sec id="s3-2-1">
<title>3.2.1 Background value and linearity of the calibration curve</title>
<p>The background value of LSC is important to <sup>3</sup>H-labeled SEP and is closely related to the sensitivity of detection expressed by LLOQ. Before each sample measurement, background values should be verified to ensure that the instrument has not been contaminated. In this test, the LLOQ of <sup>3</sup>H-SEP was 4 Bq, which ensured that the analysis of experiment samples was accurate. The correlation coefficient (r) of standard calibration curves was 1, showing good linearity. The regression equation of the calibration curve was Y &#x3d; 0.333 &#x2b; 0.980X. The limit of detection (LOD) was 1 Bq.</p>
</sec>
<sec id="s3-2-2">
<title>3.2.2 Accuracy and precision</title>
<p>The intra-day and inter-day precision of <sup>3</sup>H-SEP in blank plasma of rats and beagles were less than 3.0% and 3.9%, respectively, of all levels (8 Bq, 40 Bq, and 320 Bq). As shown in <xref ref-type="table" rid="T1">Table 1</xref>, the accuracy ranged from 95.0% to 102.1%. These results show that the LSC method is very stable, which is also one of the advantages of isotope tracer methods. It is also considered to be reasonable and reliable to analyze the <sup>3</sup>H-SEP radioactivity in biological matrices of rats or dogs.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Precision and accuracy results for the radioactivity determination of <sup>3</sup>H-SEP in rat and beagle plasma.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="center">Radiation volume (Bq)</th>
<th colspan="2" align="center">Intra-day (<italic>n</italic> &#x3d; 5)</th>
<th colspan="2" align="center">Inter-day (<italic>n</italic> &#x3d; 15)</th>
</tr>
<tr>
<th align="center">Accuracy (mean &#xb1; SD, %)</th>
<th align="center">Precision (RSD, %)</th>
<th align="center">Accuracy (mean &#xb1; SD, %)</th>
<th align="center">Precision (RSD, %)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td colspan="5" align="center">Rats</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">99.8 &#xb1; 2.3</td>
<td align="center">6.8</td>
<td align="center">98.9 &#xb1; 1.8</td>
<td align="center">1.7</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">98.9 &#xb1; 3.9</td>
<td align="center">3.0</td>
<td align="center">102.7 &#xb1; 3.5</td>
<td align="center">3.9</td>
</tr>
<tr>
<td align="center">40</td>
<td align="center">99.2 &#xb1; 3.5</td>
<td align="center">2.1</td>
<td align="center">100.4 &#xb1; 2.0</td>
<td align="center">3.0</td>
</tr>
<tr>
<td align="center">320</td>
<td align="center">98.6 &#xb1; 1.5</td>
<td align="center">1.1</td>
<td align="center">96.7 &#xb1; 1.1</td>
<td align="center">1.9</td>
</tr>
<tr>
<td colspan="5" align="center">Beagles</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">97.5 &#xb1; 1.3</td>
<td align="center">7.6</td>
<td align="center">98.5 &#xb1; 1.5</td>
<td align="center">1.8</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">92.9 &#xb1; 3.0</td>
<td align="center">3.2</td>
<td align="center">93.3 &#xb1; 3.3</td>
<td align="center">3.5</td>
</tr>
<tr>
<td align="center">40</td>
<td align="center">100.3 &#xb1; 1.8</td>
<td align="center">1.8</td>
<td align="center">98.2 &#xb1; 2.5</td>
<td align="center">1.9</td>
</tr>
<tr>
<td align="center">320</td>
<td align="center">99.3 &#xb1; 1.6</td>
<td align="center">1.6</td>
<td align="center">99.7 &#xb1; 1.6</td>
<td align="center">1.6</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-2-3">
<title>3.2.3 Quenching effect</title>
<p>The quenching effect is the exclusive characteristic of the determination of LSC, which demonstrates the influence of plasma on radioactivity analysis. In the current study, the blank rat or dog plasma mixed with stock solution had no obvious effect on the analysis. In the protocol, the results suggest that no serious quenching effect existed in biological matrices.</p>
</sec>
<sec id="s3-2-4">
<title>3.2.4 Stability</title>
<p>The tritium&#x2013;water exchange rate is another way to verify the stability of <sup>3</sup>H-SEP in diluent and plasma, either in rats or in beagles. As shown in <xref ref-type="table" rid="T2">Table 2</xref>, there was no significant change in the stability of QC samples under different conditions. The deviation was within 8.2% of theoretical concentration under four established conditions.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Stability results for <sup>3</sup>H-SEP in rat and beagle plasma.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Stability condition</th>
<th align="center">Radiation volume (Bq)</th>
<th align="center">Mean &#xb1; SD</th>
<th align="center">RSD (%)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td colspan="4" align="center">Rat</td>
</tr>
<tr>
<td align="center">&#x2003;Short-term stability (25&#xb0;C, 4&#xa0;h)</td>
<td align="center">8</td>
<td align="center">7.9 &#xb1; 0.4</td>
<td align="center">4.5</td>
</tr>
<tr>
<td align="center"/>
<td align="center">40</td>
<td align="center">40.0 &#xb1; 1.3</td>
<td align="center">3.3</td>
</tr>
<tr>
<td align="center"/>
<td align="center">320</td>
<td align="center">314.9 &#xb1; 2.1</td>
<td align="center">0.7</td>
</tr>
<tr>
<td align="center">&#x2003;Post-preparative stability (4&#xb0;C, 24&#xa0;h)</td>
<td align="center">8</td>
<td align="center">8.3 &#xb1; 0.7</td>
<td align="center">8.2</td>
</tr>
<tr>
<td align="center"/>
<td align="center">40</td>
<td align="center">37.9 &#xb1; 0.7</td>
<td align="center">2.0</td>
</tr>
<tr>
<td align="center"/>
<td align="center">320</td>
<td align="center">316.5 &#xb1; 2.5</td>
<td align="center">0.8</td>
</tr>
<tr>
<td align="center">&#x2003;Long-term storage stability (-20&#xb0;C, 30 days)</td>
<td align="center">8</td>
<td align="center">8.0 &#xb1; 0.2</td>
<td align="center">2.6</td>
</tr>
<tr>
<td align="center"/>
<td align="center">40</td>
<td align="center">39.5 &#xb1; 0.7</td>
<td align="center">1.8</td>
</tr>
<tr>
<td align="center"/>
<td align="center">320</td>
<td align="center">311.4 &#xb1; 3.4</td>
<td align="center">1.1</td>
</tr>
<tr>
<td align="center">&#x2003;Three freeze&#x2013;thaw cycles (-20&#xb0;C)</td>
<td align="center">8</td>
<td align="center">8.0 &#xb1; 0.3</td>
<td align="center">3.5</td>
</tr>
<tr>
<td align="center"/>
<td align="center">40</td>
<td align="center">39.1 &#xb1; 1.4</td>
<td align="center">3.5</td>
</tr>
<tr>
<td align="center"/>
<td align="center">320</td>
<td align="center">305.9 &#xb1; 2.7</td>
<td align="center">0.9</td>
</tr>
<tr>
<td colspan="4" align="center">Beagle</td>
</tr>
<tr>
<td align="center">&#x2003;Short-term stability (25&#xb0;C, 4&#xa0;h)</td>
<td align="center">8</td>
<td align="center">7.3 &#xb1; 0.2</td>
<td align="center">3.2</td>
</tr>
<tr>
<td align="center"/>
<td align="center">40</td>
<td align="center">39.8 &#xb1; 0.7</td>
<td align="center">1.6</td>
</tr>
<tr>
<td align="center"/>
<td align="center">320</td>
<td align="center">315.8 &#xb1; 2.9</td>
<td align="center">0.9</td>
</tr>
<tr>
<td align="center">&#x2003;Post-preparative stability (4&#xb0;C, 24&#xa0;h)</td>
<td align="center">8</td>
<td align="center">7.51 &#xb1; 0.2</td>
<td align="center">2.6</td>
</tr>
<tr>
<td align="center"/>
<td align="center">40</td>
<td align="center">39.7 &#xb1; 0.4</td>
<td align="center">0.9</td>
</tr>
<tr>
<td align="center"/>
<td align="center">320</td>
<td align="center">318.9 &#xb1; 5.4</td>
<td align="center">1.7</td>
</tr>
<tr>
<td align="center">&#x2003;Long-term storage stability (&#x2212;20&#xb0;C, 30 days)</td>
<td align="center">8</td>
<td align="center">7.4 &#xb1; 0.3</td>
<td align="center">4.4</td>
</tr>
<tr>
<td align="center"/>
<td align="center">40</td>
<td align="center">39.8 &#xb1; 0.5</td>
<td align="center">1.4</td>
</tr>
<tr>
<td align="center"/>
<td align="center">320</td>
<td align="center">316.4 &#xb1; 1.9</td>
<td align="center">0.6</td>
</tr>
<tr>
<td align="center">&#x2003;Three freeze&#x2013;thaw cycles (-20&#xb0;C)</td>
<td align="center">8</td>
<td align="center">7.2 &#xb1; 0.1</td>
<td align="center">1.1</td>
</tr>
<tr>
<td align="center"/>
<td align="center">40</td>
<td align="center">39.9 &#xb1; 0.6</td>
<td align="center">1.4</td>
</tr>
<tr>
<td align="center"/>
<td align="center">320</td>
<td align="center">321.7 &#xb1; 2.3</td>
<td align="center">0.7</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="s3-3">
<title>3.3 Pharmacokinetic study</title>
<p>The authenticity value of SEP was calculated based on <sup>3</sup>H-SEP radioactivity in rat and beagle plasma after intravenous administration. It was sensitive enough to determine the plasma concentration up to 96.0&#xa0;h. The mean plasma concentration&#x2013;time profiles of SEP are shown in <xref ref-type="fig" rid="F2">Figures 2</xref>, <xref ref-type="fig" rid="F3">3</xref>, and calculated pharmacokinetic parameters are exhibited in <xref ref-type="table" rid="T3">Table 3</xref>. The concentration of SEP in plasma from different species and three dose groups declined with a similar trend, dramatically decreasing within 30&#xa0;min of administration and being eliminated slowly. Compared with single administration, concentrations determined at each point for multiple administration were all relatively high. The half-life of SEP is 35.48 and 204.29&#xa0;h in rats and dogs, respectively. As shown in <xref ref-type="table" rid="T3">Table 3</xref>, the AUC<sub>(0-t)</sub> value of SEP increased proportionately with dose in both rats and beagles. The CL<sub>z</sub> values for the middle- and high-dose-level groups were slightly higher than that of the low-level dose group.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Logarithmic graph of mean plasma concentration&#x2013;time profiles in rats after intravenous injection of SEP (single doses of 20, 40, or 80&#xa0;mg/kg or multiple doses of 40&#xa0;mg/kg on the seventh day).</p>
</caption>
<graphic xlink:href="fphar-14-1109084-g002.tif"/>
</fig>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Logarithmic graph of mean plasma concentration&#x2013;time profiles in beagles after intravenous injection of SEP (single doses of 5, 10, or 20&#xa0;mg/kg or multiple doses of 10&#xa0;mg/kg on the seventh day).</p>
</caption>
<graphic xlink:href="fphar-14-1109084-g003.tif"/>
</fig>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Pharmacokinetic parameters of SEP after intravenous injection in rats (<italic>n</italic> &#x3d; 6) and beagles (<italic>n</italic> &#x3d; 4).</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="center">Parameter</th>
<th colspan="4" align="center">Rat</th>
</tr>
<tr>
<th align="center">20&#xa0;mg/kg</th>
<th align="center">40&#xa0;mg/kg</th>
<th align="center">80&#xa0;mg/kg</th>
<th align="center">40&#xa0;mg/kg (multiple dose)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">AUC<sub>(0-t)</sub> <sub>(</sub>mg/L&#x2a;h)</td>
<td align="center">487.81 &#xb1; 39.99</td>
<td align="center">1,003.10 &#xb1; 95.94</td>
<td align="center">2,188.84 &#xb1; 137.73</td>
<td align="center">1,216.00 &#xb1; 134.12</td>
</tr>
<tr>
<td align="center">AUC<sub>(0-&#x221e;)</sub> <sub>(</sub>mg/L&#x2a;h)</td>
<td align="center">599.91 &#xb1; 65.65</td>
<td align="center">1,148.35 &#xb1; 111.49</td>
<td align="center">2,772.41 &#xb1; 261.40</td>
<td align="center">1,656.72 &#xb1; 235.18</td>
</tr>
<tr>
<td align="center">t<sub>1/2z</sub> (h)</td>
<td align="center">43.33 &#xb1; 6.11</td>
<td align="center">35.48 &#xb1; 6.04</td>
<td align="center">46.51 &#xb1; 8.46</td>
<td align="center">55.93 &#xb1; 17.41</td>
</tr>
<tr>
<td align="center">T<sub>max</sub> (h)</td>
<td align="center">0.03 (0.03,0.03)</td>
<td align="center">0.03 (0.03,0.03)</td>
<td align="center">0.03 (0.03,0.03)</td>
<td align="center">0.03 (0.03,0.03)</td>
</tr>
<tr>
<td align="center">CL<sub>z</sub> (L/h/kg)</td>
<td align="center">0.03 &#xb1; 0.00</td>
<td align="center">0.04 &#xb1; 0.00</td>
<td align="center">0.03 &#xb1; 0.00</td>
<td align="center">0.04 &#xb1; 0.00</td>
</tr>
<tr>
<td align="center">V<sub>z</sub> (L/kg)</td>
<td align="center">2.09 &#xb1; 0.21</td>
<td align="center">1.79 &#xb1; 0.31</td>
<td align="center">1.93 &#xb1; 0.21</td>
<td align="center">1.90 &#xb1; 0.57</td>
</tr>
<tr>
<td align="center">C<sub>max</sub> (mg/L)</td>
<td align="center">58.69 &#xb1; 4.86</td>
<td align="center">140.72 &#xb1; 7.86</td>
<td align="center">277.96 &#xb1; 13.90</td>
<td align="center">136.95 &#xb1; 9.24</td>
</tr>
</tbody>
</table>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="center">Parameter</th>
<th colspan="4" align="center">Beagle</th>
</tr>
<tr>
<th align="center">5&#xa0;mg/kg</th>
<th align="center">10&#xa0;mg/kg</th>
<th align="center">20&#xa0;mg/kg</th>
<th align="center">10&#xa0;mg/kg (multiple dose)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">Parameter</td>
<td align="center">5&#xa0;mg/kg</td>
<td align="center">10&#xa0;mg/kg</td>
<td align="center">20&#xa0;mg/kg</td>
<td align="center">10&#xa0;mg/kg (multiple dose)</td>
</tr>
<tr>
<td align="center">AUC<sub>(0-t)</sub> <sub>(</sub>mg/L&#x2a;h)</td>
<td align="center">144.12 &#xb1; 3.78</td>
<td align="center">322.62 &#xb1; 28.03</td>
<td align="center">754.17 &#xb1; 37.79</td>
<td align="center">517.76 &#xb1; 28.34</td>
</tr>
<tr>
<td align="center">AUC<sub>(0-&#x221e;)</sub> <sub>(</sub>mg/L&#x2a;h)</td>
<td align="center">474.45 &#xb1; 205.71</td>
<td align="center">1,051.64 &#xb1; 648.17</td>
<td align="center">1941.52 &#xb1; 158.62</td>
<td align="center">1831.56 &#xb1; 461.00</td>
</tr>
<tr>
<td align="center">t<sub>1/2z</sub> (h)</td>
<td align="center">221.61 &#xb1; 121.30</td>
<td align="center">204.29 &#xb1; 139.34</td>
<td align="center">153.88 &#xb1; 24.15</td>
<td align="center">279.45 &#xb1; 461.00</td>
</tr>
<tr>
<td align="center">T<sub>max</sub> (h)</td>
<td align="center">0.03 (0.03,0.03)</td>
<td align="center">0.03 (0.03,0.03)</td>
<td align="center">0.03 (0.03,0.03)</td>
<td align="center">0.03 (0.03,0.03)</td>
</tr>
<tr>
<td align="center">CL<sub>z</sub> (L/h/kg)</td>
<td align="center">0.01 &#xb1; 0.01</td>
<td align="center">0.01 &#xb1; 0.01</td>
<td align="center">0.03 &#xb1; 0.00</td>
<td align="center">0.01 &#xb1; 0.00</td>
</tr>
<tr>
<td align="center">V<sub>z</sub> (L/kg)</td>
<td align="center">3.23 &#xb1; 0.50</td>
<td align="center">2.74 &#xb1; 0.17</td>
<td align="center">2.28 &#xb1; 0.18</td>
<td align="center">2.85 &#xb1; 0.31</td>
</tr>
<tr>
<td align="center">C<sub>max</sub> (mg/L)</td>
<td align="center">22.03 &#xb1; 0.92</td>
<td align="center">42.00 &#xb1; 5.42</td>
<td align="center">105.19 &#xb1; 10.81</td>
<td align="center">45.35 &#xb1; 1.36</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Note: All data are presented as mean &#xb1; SD, except for T<sub>max</sub> values, presented as median (min, max).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>4 Discussion</title>
<p>Marine anticancer drug research has always played a leading role in marine drug research (<xref ref-type="bibr" rid="B10">Khalifa et al., 2019</xref>; <xref ref-type="bibr" rid="B15">Ren et al., 2021</xref>). Compared with chemical synthetic drugs, pharmaceutical ingredients taken from natural marine organisms have lower toxicity and higher safety, and they can selectively identify cancer-related factors, thereby inhibiting the growth or causing the death of tumor cells (<xref ref-type="bibr" rid="B4">de Jesus Raposo et al., 2015</xref>). At the same time, these ingredients avoid damage to normal cells in the human body, effectively treat the disease, and greatly reduce the side effects of drugs. SEP extracted from <italic>Strongylocentrotus nudus</italic> sea urchin eggs has the advantage of natural anticancer active ingredients. Unlike synthetic chemical compounds, SEP is a biological macromolecule with a molecular weight of 1.63&#x2a;10<sup>5</sup>&#xa0;Da, so it is hard to identify it quantitatively and to conduct pharmacokinetic studies for SEP using conventional methods. Radioisotopes have been proven to be essential in biomedical study and have played a vital role in studying the pharmacokinetic properties of new chemical compounds, including their absorption, distribution, metabolism, and excretion (ADME) (<xref ref-type="bibr" rid="B3">Dalvie, 2000</xref>). Common methods of isotope labeling include chemical synthesis, biochemistry, and isotope exchange, and the most widely used nuclides include 3H, 14C, 35S, 32P, 76Br, and 125I (<xref ref-type="bibr" rid="B6">Fu et al., 2010</xref>). In this study, tritium was selected as the tracer to label SEP to investigate the pharmacokinetics of SEP in rats and beagles.</p>
<p>According to the results of method verification, the tritium tracer method is stable, guaranteeing the authenticity and reliability of the SEP pharmacokinetic results. In rats and beagles, the concentration of SEP in plasma was reduced by 90% within 24&#xa0;h of administration, while the remaining 10% was metabolized more slowly. This phenomenon may be related to the characteristics of tritium-labeled isotope tracing (<xref ref-type="bibr" rid="B22">Yang et al., 2012b</xref>). In this study, radiation rather than SEP was quantitatively measured, and the concentration of SEP was then calculated based on the proportion. Therefore, the radiation measured after 24&#xa0;h is likely not derived from <sup>3</sup>H-SEP but from SEP metabolites or metabolized tritium water (<xref ref-type="bibr" rid="B22">Yang et al., 2012b</xref>). It is worth noting that its pharmacokinetic profile does not meet the typical compartment model, possibly because the plasma concentration determined was converted from the total radioactivity, which was the sum of parent SEP and its radioactive metabolites; this is a shortcoming of the tritium tracer method. This is also why the AUC extrapolation ratio of beagles is too large. Compared to AUC<sub>(0-&#x221e;)</sub>, the AUC<sub>(0-t)</sub> of SEP is more credible and should be used as a basis for further development.</p>
<p>Being similar to traditional chemicals, multiple dosing administration of SEP was also applied to investigate the possibility of accumulation. In general, anticancer drugs must be administered continuously, so the accumulated results in the body should be noted in future clinical studies. The results of this study preliminarily show the application of tritium marker tracer SEP in rats and beagles, providing a new idea for the study of polysaccharide pharmacokinetics and forming the basis of further research on the pharmacokinetics and pharmacodynamics of SEP. In other words, the relationship between the concentration of SEP at the target site and the efficacy concentration requires more attention.</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>5 Conclusion</title>
<p>Tritium-labeled SEP was synthesized, and a reliable LSC radioisotope detection method was developed and successfully applied to pharmacokinetic studies in rats and beagles. An apparent decrease was observed after intravenous injection, according to the plasma concentration results, which was contrary to elimination in both rats and beagles. This study further investigated the pharmacokinetics of SEP <italic>in vivo</italic> and will promote the development of SEP as a new anticancer candidate.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s7">
<title>Ethics statement</title>
<p>The animal study was reviewed and approved by the Animal Ethics Committee of China Pharmaceutical University.</p>
</sec>
<sec id="s8">
<title>Author contributions</title>
<p>Data collection and statistical analysis: HX, ZQ, XZ, YK, and YL; design of the study: XC, JL, ZQ, and HX; analysis and interpretation of the data: HX and ZQ; drafting the manuscript: HX and ZQ; critical revision of the manuscript: DZ and NL.</p>
</sec>
<sec id="s9">
<title>Funding</title>
<p>This study was supported by the Foundation of the He&#x2019;nan Educational Committee (21A350014) and the Medical Science and Technology Research Program of Henan Province (LHGJ20200284 and LHGJ20220420).</p>
</sec>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Behranvand</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nasri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zolfaghari Emameh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Khani</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hosseini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garssen</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Chemotherapy: A double-edged sword in cancer treatment</article-title>. <source>Cancer Immunol. Immunother.</source> <volume>71</volume> (<issue>3</issue>), <fpage>507</fpage>&#x2013;<lpage>526</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-021-03013-3</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Bioactive polysaccharides from traditional Chinese medicine herbs as anticancer adjuvants</article-title>. <source>J. Altern. Complementary Med.</source> <volume>8</volume> (<issue>5</issue>), <fpage>559</fpage>&#x2013;<lpage>565</lpage>. <pub-id pub-id-type="doi">10.1089/107555302320825066</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalvie</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Recent advances in the applications of radioisotopes in drug metabolism, toxicology and pharmacokinetics</article-title>. <source>Curr. Pharm. Des.</source> <volume>6</volume> (<issue>10</issue>), <fpage>1009</fpage>&#x2013;<lpage>1028</lpage>. <pub-id pub-id-type="doi">10.2174/1381612003399941</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Jesus Raposo</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>de Morais</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>de Morais</surname>
<given-names>R. M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Marine polysaccharides from algae with potential biomedical applications</article-title>. <source>Mar. Drugs</source> <volume>13</volume> (<issue>5</issue>), <fpage>2967</fpage>&#x2013;<lpage>3028</lpage>. <pub-id pub-id-type="doi">10.3390/md13052967</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edelmann</surname>
<given-names>M. R.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Radiolabelling small and biomolecules for tracking and monitoring</article-title>. <source>RSC Adv.</source> <volume>12</volume> (<issue>50</issue>), <fpage>32383</fpage>&#x2013;<lpage>32400</lpage>. <pub-id pub-id-type="doi">10.1039/d2ra06236d</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Molecular imaging of MDM2 messenger RNA with 99mTc-labeled antisense oligonucleotides in experimental human breast cancer xenografts</article-title>. <source>J. Nucl. Med.</source> <volume>51</volume> (<issue>11</issue>), <fpage>1805</fpage>&#x2013;<lpage>1812</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.110.077982</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dou</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Antitumor activity of the polysaccharride from the eggs of Strongylocentrotus nudus(SEP) on S180 <italic>in vivo</italic>
</article-title>. <source>Chin. J. Cell Biol.</source>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Leithold</surname>
<given-names>L. H. E.</given-names>
</name>
<name>
<surname>Post</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ziehm</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mauler</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gremer</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Preclinical pharmacokinetic studies of the tritium labelled D-enantiomeric peptide D3 developed for the treatment of Alzheimer&#xb4;s disease</article-title>. <source>Plos One</source> <volume>10</volume> (<issue>6</issue>), <fpage>e0128553</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0128553</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>The anti-lung cancer activity of SEP is mediated by the activation and cytotoxicity of NK cells via TLR2/4 <italic>in vivo</italic>
</article-title>. <source>Biochem. Pharmacol.</source> <volume>89</volume> (<issue>1</issue>), <fpage>119</fpage>&#x2013;<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2014.02.024</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khalifa</surname>
<given-names>S. A. M.</given-names>
</name>
<name>
<surname>Elias</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Farag</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Saeed</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hegazy</surname>
<given-names>M. F.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Marine natural products: A source of novel anticancer drugs</article-title>. <source>Mar. Drugs</source> <volume>17</volume> (<issue>9</issue>), <fpage>491</fpage>. <pub-id pub-id-type="doi">10.3390/md17090491</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it</article-title>. <source>Biomed. Pharmacother.</source> <volume>100</volume>, <fpage>441</fpage>&#x2013;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.02.055</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Immunomodulatory activity of polysaccharides isolated from Strongylocentrotus nudus eggs</article-title>. <source>Int. Immunopharmacol.</source> <volume>8</volume> (<issue>13-14</issue>), <fpage>1835</fpage>&#x2013;<lpage>1841</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2008.09.005</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Immunomodulatory activity of polysaccharides isolated from Strongylocentrotus nudus eggs</article-title>. <source>Int. Immunopharmacol.</source> <volume>8</volume> (<issue>13-14</issue>), <fpage>1835</fpage>&#x2013;<lpage>1841</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2008.09.005</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ooi</surname>
<given-names>V. E.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Immunomodulation and anti-cancer activity of polysaccharide-protein complexes</article-title>. <source>Curr. Med. Chem.</source> <volume>7</volume> (<issue>7</issue>), <fpage>715</fpage>&#x2013;<lpage>729</lpage>. <pub-id pub-id-type="doi">10.2174/0929867003374705</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Marine natural products: A potential source of anti-hepatocellular carcinoma drugs</article-title>. <source>J. Med. Chem.</source> <volume>64</volume> (<issue>12</issue>), <fpage>7879</fpage>&#x2013;<lpage>7899</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c02026</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Strongylocentrotus nudos Egg Polysaccharide induces autophagy and apoptosis in leukaemia cells by regulating mitochondrial function</article-title>. <source>J. Cell Mol. Med.</source> <volume>25</volume>, <fpage>272</fpage>&#x2013;<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.15995</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>A polysaccharide from Strongylocentrotus nudus eggs protects against myelosuppression and immunosuppression in cyclophosphamide-treated mice</article-title>. <source>Int. Immunopharmacol.</source> <volume>11</volume> (<issue>11</issue>), <fpage>1946</fpage>&#x2013;<lpage>1953</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2011.06.006</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Effective inhibition of a Strongylocentrotus nudus eggs polysaccharide against hepatocellular carcinoma is mediated via immunoregulation <italic>in vivo</italic>
</article-title>. <source>Immunol. Lett.</source> <volume>141</volume> (<issue>1</issue>), <fpage>74</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.imlet.2011.08.001</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dou</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-&#x3ba;B pathway <italic>in vitro</italic>/vivo</article-title>. <source>Carbohydr. Polym.</source> <volume>225</volume>, <fpage>115223</fpage>. <pub-id pub-id-type="doi">10.1016/j.carbpol.2019.115223</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Talbi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Pharmacokinetics study of calf thymus DNA in rats and beagle dogs with (3)H-labeling and tracing method</article-title>. <source>J. Pharm. Biomed. Analysis</source> <volume>88</volume> (<comment>Complete</comment>), <fpage>60</fpage>&#x2013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpba.2013.08.016</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Pharmacokinetics and disposition study of calf thymus DNA in rats by applying 3H-labeling method</article-title>. <source>J. Pharm. Biomed. Analysis</source> <volume>64-65</volume> (<issue>6</issue>), <fpage>35</fpage>&#x2013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpba.2012.02.012</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Pharmacokinetics and disposition study of calf thymus DNA in rats by applying 3H-labeling method</article-title>. <source>J. Pharm. Biomed. Anal.</source> <volume>64-65</volume>, <fpage>35</fpage>&#x2013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpba.2012.02.012</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dou</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>A polysaccharide component from Strongylocentrotus nudus eggs inhibited hepatocellular carcinoma in mice by activating T lymphocytes</article-title>. <source>Oncol. Lett.</source> <volume>13</volume> (<issue>3</issue>), <fpage>1847</fpage>&#x2013;<lpage>1855</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2017.5624</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The synthesis of nano-doxorubicin and its anticancer effect</article-title>. <source>Anticancer Agents Med. Chem.</source> <volume>21</volume> (<issue>18</issue>), <fpage>2466</fpage>&#x2013;<lpage>2477</lpage>. <pub-id pub-id-type="doi">10.2174/1871520621666201229115612</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zong</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Anticancer polysaccharides from natural resources: A review of recent research</article-title>. <source>Carbohydr. Polym.</source> <volume>90</volume> (<issue>4</issue>), <fpage>1395</fpage>&#x2013;<lpage>1410</lpage>. <pub-id pub-id-type="doi">10.1016/j.carbpol.2012.07.026</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zraik</surname>
<given-names>I. M.</given-names>
</name>
<name>
<surname>He&#xdf;-Busch</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2021</year>). [<article-title>Management of chemotherapy side effects and their long-term sequelae</article-title>]. <source>Urol. A</source> <volume>60</volume> (<issue>7</issue>), <fpage>862</fpage>&#x2013;<lpage>871</lpage>. <pub-id pub-id-type="doi">10.1007/s00120-021-01569-7</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>